Which Has The Best Potential? Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), Axalta Coating Systems Ltd (NYSE:AXTA) and IsoRay, Inc. (NYSEMKT:ISR)

Posted by admin April 30, 2015 0 Comment 430 views

New York, NY – GDP INSIDER  –  04/30/2014.

This article discusses three companies: Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), Axalta Coating Systems Ltd (NYSE:AXTA) and IsoRay, Inc. (NYSEMKT:ISR)

Ampio Pharmaceuticals Inc(NYSEMKT:AMPE) continued to decline yesterday with the stock closing down 4.49% or $0.12 to finish the day at $2.55, on light trading of 0.904 million shares compared to its three month average trading volume of 1.15 million. The stock has been vastly underperforming the S&P 500 so far this year, posting a loss of 25.66% year to date compared to the S&P 500 which is currently up 2.39% for the same period. With RSI now at 22.68 the stock may be undervalued at the moment, but is a very speculative buy.
Are Ampio Pharmaceuticals Inc’s Shares OverValued? Get Our Free AMPE Analysis To Know More.

Axalta Coating Systems Ltd (NYSE:AXTA) reversed its recent downward trend yesterday with the stock closing up 1.37% or $0.42 to finish the day at a closing price of $31.00 on heavy trading of 1.52 million compared to its three month average trading volume of 1.10 million. The coating and paint systems designer and manufacturer, which traded within a range of $30.32 to $31.04 during the day, currently situated 54.15% above its 52 week low of $20.11 and 3.97% below its 52 week high of $32.28. The RSI of 56.99 indicates the stock is not overbought at the current levels and may continue to climb making it a positive hold and potential buy.

Find Out Whether Axalta Coating Systems Ltd Can Manage To Keep Climbing With Our Free AXTA Analysis.

IsoRay, Inc. (NYSEMKT:ISR) continued its strong upward trend on Wednesday with the stock gaining another 16.33% or $0.24 to close at $1.71 with more than 3.19 million shares changing hands, compared to its 30 day average trading volume of 0.568 million. IsoRay, Inc’s drastic increase in value came despite the fact that the company did not make any significant announcements or release any financial figures. Currently, the RSI and MFI for the innovator in seed brachytherapy and medial radioisotope cancer treatments are 64 and 63, respectively, which indicate that there is not the expectation from technical that yesterday’s gains will reverse.

Are IsoRay, Inc’s Technical Indicators Showing Further Gains? Delve Into The Details With Free ISR Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

Write Your Comment